Search
Powered By HealthLine
Special Offers
Health Tools
 Cold & Flu Remedies
 Symptoms Checker
 Quiz: Cold & Flu Myths
 Flu Vaccine Guide
 Avian Flu Guide
Featured Conditions
 Cold & Flu
 Allergy
 Diet & Exercise
 Depression
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

FDA Panel Backs Tougher Warning on Asthma Drugs for Kids


Related Encyclopedia
 border=
Abscess
Acidophilus
Acne
Actinomycosis
More...

Related Healthscout Videos
 border=
Nutrition and Cancer
Nutrition and Osteoporosis
Importance of Good Nutrition
Picture Perfect Smile
More...

Related Animations
 border=
Dental Cavities
More...

Related Drug Information
 border=
Abilify
Adderal XR
Augmentin
Bactroban Cream
More...

Related News Articles
 border=
Substitutions Make Holiday Fare Healthier
High Blood Pressure Stalks Many Americans
Getting Tough on Bullying
Health Tip: Signs of Celiac Disease in Children
More...


Page:  << Prev | 1 | 2 | 3 | Next >>

The drug's label mentions reports of delirium and self-injury, primarily among children in Japan, but the advisory panel said the language should state that several patients died as a result of these behaviors, AP reported.

A spokeswoman for Roche said Wednesday that all flu patients, not just those taking Tamiflu, should be warned that the illness posed a risk of psychiatric problems. She stressed there was no causal relationship between Tamiflu and the reported cases of delirium and hallucinations, AP reported.

In addition, the FDA panel recommended that labeling for the flu drug Relenza, (zanamivir), should also reflect reports of abnormal behavior, according to Bloomberg.

Text Continues Below



The FDA is not obliged to follow its expert panels' recommendation, but it usually does. A safety review released Friday by the FDA's Division of Antiviral Products urged stronger label warnings for both flu drugs, including stricter monitoring of children taking these drugs.

According to the FDA safety review, there have been 596 reported cases of psychiatric behavior associated with Tamiflu use. Most of these cases happened among patients aged 21 or younger. The majority (75 percent) occurred in Japan.

Fifty-nine of the cases were classified as delirium with impulsive behavior and self-injury. Delirium, delusions, hallucinations or psychosis accounted for another 225 cases. In total, five children died "as a result of falls from windows or balconies or running into traffic," the safety review found, and three adults committed suicide. So far, there haven't been any such cases reported in the United States, according to the FDA.

The FDA safety review also reported that in cases involving Relenza, mostly in Japan, there have been 115 reports of "delirium with impulsive behavior and self-injury in which the patient expressed 'fear' and attempted to flee or expressed a desire to 'jump,'" the agency said. There were no deaths associated with Relenza.

Page:  << Prev | 1 | 2 | 3 | Next >>

Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 11/28/2007

Related Links
 border=
From Healthscout's partner site on allergy, MyAllergyNetwork.com
QUIZ: Test your knowledge of allergy causes and treatments
DRUGS: Common drugs used to treat allergies
SYMPTOMS: Images and information on allergy symptoms





SOURCES: Pediatric Safety Update for Tamiflu, Division of Antiviral Products, U.S. Food and Drug Administration; Nov. 27, 2007, statements, GlaxoSmithKline and Roche; Bloomberg news; Associated Press, MarketWatch


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map